logo-loader
RNS
Nuformix PLC

Nuformix PLC - AGM Results

RNS Number : 8767L
Nuformix PLC
10 September 2019
 

10th September 2019

 

Nuformix plc

("Nuformix" or "the Group"),

 

Result of Annual General Meeting

 

The Annual General Meeting of Nuformix plc was held on 10th September 2019 at 1.00pm, at the offices of Shakespeare Martineau LLP, 60 Gracechurch Street, London, EC3V 0HR.

 

As announced this morning resolution 7 was withdrawn from the meeting. The Directors of the Company wish to announce that all other resolutions put to shareholders were duly passed and approved on a show of hands at the meeting.  The results of the proxy voting position received in advance of the meeting are reported below:

 


Resolution

Ordinary/ Special

For


Against


Total votes cast




No. of votes

%

No. of votes

%


1

To receive the annual report and accounts for the year ended 31 March 2019

 

Ordinary

121,471,999

100

0

0

121,471,999

2

To approve the Annual Report on Remuneration

 

Ordinary

121,413,979

 

100

0

0

121,413,979

 

3

To re-appoint David Tapolczay as a director

 

Ordinary

121,465,547

 

100

0

0

121,465,547

 

4

To re-appoint Daniel Gooding as a director

 

Ordinary

121,471,999

 

100

0

0

121,471,999

 

5

To re-appoint Joanne Holland as a director

 

Ordinary

121,465,547

 

100

0

0

121,465,547

 

6

To re-appoint John Lidgey as a director

 

Ordinary

83,841,906

 

99.85

123,641

 

0.15

83,965,547

 

7

To re-appoint Kirk Siderman-Wolter as a director

 

Ordinary

Withdrawn





8

To re-Christopher Blackwell as a director

 

Ordinary

121,465,547

 

100

0

0

121,465,547

 

9

To re-appoint haysmacintyre as auditor

 

Ordinary

121,465,547

 

100

0

0

121,465,547

 

10

To authorise the Directors to determine the auditor's fees.

 

Ordinary

121,465,547

 

100

0

0

121,465,547

 

11

To authorise the Directors to allot shares.

 

Ordinary

121,471,999

 

100

0

0

121,471,999

 

12

To authorise the Directors to disapply pre-emption rights.

 

Special

121,465,547

 

100

0

0

121,465,547

 

13

To authorise the Company to purchase its own shares.

 

Special

121,471,999

 

100

0

0

121,471,999

 

14

To authorise calling of a general meeting on 14 clear days' notice.

 

Special

121,471,999

 

100

0

0

121,471,999

 

 

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

 

The Company's issued share capital is 469,466,512 ordinary shares of £0.001 each. Copies of the resolutions passed as special resolutions at the AGM will shortly be available for inspection at the National Storage Mechanism, which is located at: http://www.morningstar.co.uk/uk/nsm.

 

Enquiries:

Nuformix plc

Dr Dan Gooding, Chief Executive Officer

+44 (0)1223 423667

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur

Email: nuformix@optimumcomms.com

+44 (0) 203 950 9144

 

 

About Nuformix plc: www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

 

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

 

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. 

 

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGLLFSEADIILIA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read